On February 18, 2026, Cencora and Covetrus announced a definitive agreement to merge Covetrus with MWI Animal Health, Cencora’s animal-health business. The proposed transaction values MWI at an enterprise value of $3.5 billion and would create a combined animal-health platform spanning distribution, pharmacy, software, and practice services.

For independent veterinary practices, this is not just another corporate transaction in the background. Distribution is where everyday medicine meets everyday business: vaccines, preventives, pharmaceuticals, supplies, equipment, online pharmacy, rebates, data tools, and the service relationships that keep shelves stocked and appointments moving.

The deal is not closed. The companies said completion is subject to customary closing conditions, including required regulatory approvals. Cencora also said its fiscal 2026 guidance does not currently assume the transaction will close before the end of its fiscal year on September 30, 2026. That matters: practices should prepare for change, but not act as if the merger is already complete.

What the companies have actually announced

Under the proposed transaction, Cencora would receive $1.25 billion in upfront cash, $800 million in preferred equity, and $1.45 billion in common equity in the combined company. Cencora would retain a non-controlling 34.3% common equity stake.

The companies describe the rationale as combining MWI’s distribution capabilities with Covetrus’ technology-enabled services. Covetrus says it serves companion, equine, and large-animal veterinary markets and offers products, software, and services to more than 100,000 customers worldwide. MWI is described as a global provider of animal-health products, services, and solutions for veterinarians and producers.

Trade coverage from Today’s Veterinary Business described the expanded platform and merger terms, while AAHA framed the veterinary distribution landscape as being on the brink of a significant shift. Both repeated the important caveat that the merger remains subject to regulatory approval and other closing requirements.

That is the confirmed picture. What is not confirmed, based on the sources reviewed here, is any active FTC investigation. A transaction of this size may receive antitrust review, and the FTC and DOJ review many large transactions under the Hart-Scott-Rodino process. But “subject to regulatory approval” is not the same as “under FTC investigation.”

Why this matters to independent practices

Independents already compete in a market where scale matters. Corporate groups can standardize purchasing, negotiate across many hospitals, and absorb back-office complexity. Independent owners often rely on distributor relationships to narrow that scale gap: local reps, negotiated pricing, rebates, online pharmacy tools, practice-management integrations, and reliable fulfillment.

A combined Covetrus-MWI would bring together two major names that many practices have historically treated as separate options. That does not automatically mean worse pricing or worse service. The companies say the combination is intended to improve logistics, create savings, and support access to animal-health products. Those benefits may prove real for some practices.

But fewer independent distribution relationships can also change negotiating dynamics. If a practice has relied on Covetrus and MWI as separate benchmarks for pricing, product availability, or service responsiveness, that comparison may become less useful after closing. The same question applies to rebates and software bundles: if savings are increasingly tied to broader platform participation, practice owners will need to understand what they are giving up in flexibility, data control, or vendor independence.

This is where independent ownership has to be intentional. The goal is not to reject large vendors. Large distributors are part of modern veterinary medicine. The goal is to avoid becoming operationally dependent on any single vendor without knowing it.

What to do before the deal closes

First, map your current spend. Break it down by distributor, manufacturer-direct purchasing, online pharmacy, equipment, software, and rebates. If Covetrus and MWI are both in your stack, identify where you use each one and why.

Second, keep more than one real option active. Patterson Veterinary remains a full-line veterinary distributor offering products, equipment, software, technology, and practice support. Manufacturer-direct programs and purchasing platforms may also play a role depending on your mix. The point is not to scatter every order; it is to preserve leverage and continuity.

Third, document service performance now. Track fill rates, backorders, shipping speed, rep responsiveness, invoice accuracy, return handling, and rebate timing. If terms change after closing, you will want facts, not impressions.

Fourth, read platform agreements carefully. Covetrus has continued to build programs aimed at independent clinics, including VetSuite, which the company said surpassed 4,000 member practices in May 2026. Those programs may offer meaningful benefits. More broadly, deeper adoption of a single vendor's bundled programs can increase a practice's reliance on that supplier. Make sure the owner, not just the inventory manager, understands the tradeoffs.

Finally, talk to your team before disruption happens. Inventory managers, practice managers, and doctors often notice supply-chain friction before ownership does. Build a simple escalation path: when a product is unavailable, a price changes sharply, or a rebate does not match expectations, someone owns the follow-up.

The takeaway

The proposed Covetrus-MWI merger is a reminder that independence is not only about who owns the clinic. It is also about how much room the clinic has to make its own operating choices.

If the merger is approved, independent practices may see new tools, broader services, or improved logistics. They may also need to reassess how the combined company affects their vendor relationships, pricing comparisons, and purchasing flexibility. The smart move now is steady and practical: know your contracts, preserve alternatives, measure service, and keep purchasing decisions tied to your practice’s needs—not a vendor’s preferred ecosystem.